Screening for prostate cancer: who and how often?

Area of Science:

• Urology
• Oncology
• Preventive Medicine

Background:

• Prostate cancer screening involves complex decisions.
• Patient engagement is crucial for informed choices.
• Shared decision-making (SDM) enhances patient understanding of benefits and risks.

Purpose of the Study:

• To evaluate the impact of patient education on shared decision-making for prostate cancer screening.
• To provide guidelines for optimal patient selection and screening frequency.

Main Methods:

• Review of educational pamphlets to enhance patient engagement.
• Analysis of lead time and sensitivity for Prostate-Specific Antigen (PSA) screening.
• Assessment of survival rates for different Gleason scores under watchful waiting.

Main Results:

• Patients reviewing educational materials before visits showed increased participation in decision-making.
• Prostate cancer screening is recommended for men with >10 years life expectancy.
• Biennial PSA screening maintains diagnostic sensitivity due to an estimated 5-7 year lead time.
• Men with Gleason score <5 demonstrate favorable 20-year survival with watchful waiting.

Conclusions:

• Patient education significantly boosts engagement in prostate cancer screening decisions.
• Targeted screening and appropriate management strategies like watchful waiting improve outcomes.
• Optimizing screening protocols enhances the effectiveness of prostate cancer care.